DNA-Repair Defects and Olaparib in Metastatic Prostate CancerJoaquı́n Mateo, Emma Hall, Johann S. de Bono et al.|New England Journal of Medicine|2015Cited by 2.2k
Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with <i>BRCA1/2</i> - and Non– <i>BRCA1/2</i> -Mutant CancersTimothy A. Yap, Johann S. de Bono, Ruth Matthews et al.|Cancer Discovery|2020Cited by 134
A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced CancerRobert H. Jones, Udai Banerji, Ruth Plummer et al.|Clinical Cancer Research|2022Cited by 41
A phase I/II first-in-human trial of oral SRA737 (a Chk1 inhibitor) given in combination with low-dose gemcitabine in subjects with advanced cancer.Udai Banerji, Robert H. Jones, Elizabeth Ruth Plummer et al.|Journal of Clinical Oncology|2019Cited by 20
Mean plasma SRA737 concentration over time from A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced CancerRobert H. Jones, Udai Banerji, Ruth Plummer et al.|Unknown|2023Cited by 2